PEG MGF 5 mg

Peptide Hubs PEG MGF

PEG MGF (Pegylated Mechano Growth Factor) by Peptide Hubs represents an advanced formulation in muscle and tissue research, presented as 5 mg of lyophilized pegylated peptide in a sterile 2 mL vial. This innovative modification of the naturally occurring IGF-1Ec isoform (also known as MGF) features polyethylene glycol (PEG) conjugation that significantly enhances its pharmacokinetic properties and research utility. Independently verified at 5.75 mg content (115% purity), this pharmaceutical-grade PEG MGF provides researchers with a precisely quantified tool for investigating muscle hypertrophy, satellite cell activation, and tissue repair mechanisms with extended activity duration compared to non-pegylated MGF.

PEG MGF Chemical Composition and Pegylation Advantages

Each vial contains 5 mg of high-purity pegylated mechano growth factor with enhanced properties:

• Base Peptide: IGF-1Ec isoform (MGF) with E-domain extension
• Sequence Region: Corresponds to human IGF-1Ec C-terminal 24 amino acids with specific modifications
• Pegylation: Covalent attachment of 5 kDa polyethylene glycol moiety to N-terminus
• Molecular Weight: Approximately 8,500-9,000 g/mol (including PEG moiety)
• Purity: >95% confirmed by size-exclusion HPLC and mass spectrometry
• Form: White lyophilized powder
• Pegylation Benefits: Extended half-life, reduced renal clearance, enhanced solubility, decreased immunogenicity
• Activity Preservation: Pegylation strategy designed to maintain receptor binding and biological activity

The strategic 5 kDa PEG conjugation represents a significant advancement over standard MGF, providing researchers with a tool that overcomes the rapid clearance limitations of the native peptide while maintaining its unique muscle-specific activities.

Research Applications in Muscle Biology and Exercise Science

PEG MGF enables sophisticated investigations across multiple research domains:

• Satellite Cell Activation Research: As a potent activator of muscle satellite cells, PEG MGF facilitates studies on muscle stem cell recruitment, proliferation, and differentiation in response to mechanical stimuli or injury.
• Muscle Hypertrophy Mechanisms: Enables investigation of localized muscle growth pathways independent of systemic IGF-1 effects, particularly the PI3K/Akt/mTOR signaling cascade in skeletal muscle.
• Exercise Adaptation Studies: Supports research on muscle memory, training adaptation, and overload-induced growth responses at cellular and molecular levels.
• Tissue Repair and Regeneration: Facilitates investigations into muscle repair following injury, with applications in sports medicine, rehabilitation, and age-related sarcopenia research.
• Metabolic Muscle Research: Enables studies on muscle glucose uptake, protein synthesis optimization, and nutrient partitioning effects specific to mechano-sensitive pathways.
• Comparative Pegylation Studies: Provides a model for investigating how pegylation affects peptide pharmacology, distribution, and activity duration in muscle tissue.

Therapeutic Research Context for Pegylated Growth Factors

While this product is for research use only, scientific literature establishes the significance of pegylated growth factors. According to research published in The Journal of Biological Chemistry, MGF expression increases dramatically in response to mechanical stimuli and plays a crucial role in mechanotransduction and muscle adaptation. Further investigation in American Journal of Physiology-Endocrinology and Metabolism demonstrated that MGF activates satellite cells through distinct signaling pathways compared to systemic IGF-1 isoforms. The pegylation technology applied to MGF represents an important research advancement, as studies indicate PEG conjugation can extend peptide half-life from minutes to hours while maintaining biological activity. These scientific foundations establish PEG MGF as a valuable tool for investigating localized muscle growth, repair mechanisms, and exercise adaptation with enhanced pharmacokinetic properties.

Research Dosage Parameters for Muscle Studies

Important: The following information is derived from published research and should only guide experimental design in appropriate research models. Always consult institutional protocols.

• In Vitro Muscle Cell Studies: Primary myoblast or satellite cell research typically uses PEG MGF concentrations of 10-100 ng/mL in differentiation media, with specific concentrations dependent on cell type and experimental endpoints.
• In Vivo Muscle Research: Animal studies commonly administer 10-100 μg/kg via intramuscular injection near target muscle groups, with exact dosing contingent on species, injection site, and research objectives.
• Reconstitution Protocol: Add 2 mL of sterile bacteriostatic water or phosphate-buffered saline (pH 7.4) to yield a concentration of 2.5 mg/mL (2500 μg/mL). Gentle swirling is recommended—avoid vigorous shaking which may damage PEG-peptide conjugate.
• Administration Routes: Intramuscular injection is preferred for localized effects; subcutaneous administration may be used for systemic distribution studies; intravenous for pharmacokinetic investigations.
• Dosing Frequency: Due to extended half-life from pegylation, dosing frequency is typically reduced compared to standard MGF—often every 2-3 days rather than daily in chronic studies.
• Local vs Systemic Effects: Research design should consider whether investigating localized muscle effects (intramuscular administration) or potential systemic actions (subcutaneous/intravenous administration).

Pharmacokinetics of Pegylated MGF

PEG conjugation dramatically alters MGF pharmacokinetics:

• Half-Life Extension: Plasma half-life extended from approximately 5-10 minutes (native MGF) to 4-8 hours (PEG MGF) in research models
• Clearance Reduction: Renal clearance reduced by 10-20 fold due to increased molecular size and decreased glomerular filtration
• Tissue Distribution: Altered distribution profile with increased accumulation in muscle tissue and reduced rapid systemic dispersion
• Metabolic Stability: Enhanced resistance to proteolytic degradation due to steric hindrance from PEG moiety
• Receptor Binding Kinetics: Slightly modified on/off rates but maintained receptor activation and downstream signaling
• Duration of Biological Effects: Extended activity window with sustained satellite cell activation and signaling pathway stimulation
• Immunogenicity: Reduced potential for antibody formation compared to non-pegylated peptide in chronic studies

Potential Research Observations in Muscle Models

Researchers should monitor for biological responses consistent with mechano growth factor activity:

• Cellular Responses: Increased satellite cell activation, myoblast proliferation, myotube formation, and muscle-specific gene expression (MyoD, myogenin, MHC)
• Signaling Pathway Activation: Enhanced phosphorylation of Akt, mTOR, p70S6K, and other hypertrophy-related signaling molecules
• Muscle Morphology Changes: Increased muscle fiber cross-sectional area, myonuclear addition, and muscle weight in appropriate models
• Functional Improvements: Enhanced muscle strength, contractile properties, and fatigue resistance in exercise or injury models
• Repair Acceleration: Faster recovery from muscle injury, reduced fibrosis, improved regeneration architecture
• Metabolic Effects: Increased muscle protein synthesis rates, improved glucose uptake, altered nutrient partitioning
• Extended Duration Effects: Prolonged biological responses compared to standard MGF due to pegylation
• Minimal Acute Toxicity: Generally well-tolerated at research doses with appropriate administration technique

Research Contraindications and Pegylation-Specific Considerations

This product is for laboratory research use only. Researchers should:

• Not administer to humans or animals for therapeutic purposes
• Exercise caution in studies involving models with PEG sensitivity or allergy (rare but documented)
• Implement appropriate monitoring for potential local reactions at intramuscular injection sites
• Use specialized techniques for pegylated peptide handling to maintain conjugate integrity
• Work in certified research facilities with appropriate equipment for pegylated compound studies
• Store securely with restricted access to prevent unauthorized use
• Dispose of materials according to institutional chemical and biohazard waste protocols
• Consider potential antibody formation in long-term studies, though reduced with pegylation
• Account for altered pharmacokinetics in experimental design and data interpretation
• Consult with institutional animal care committees regarding appropriate monitoring for muscle studies

Overdose Considerations in Muscle Research

Administration significantly above established research parameters may produce exaggerated musculoskeletal effects including disproportionate muscle growth, connective tissue strain, or metabolic disturbances that could compromise animal welfare and study validity. Researchers should establish careful dose-escalation protocols and implement comprehensive monitoring including muscle function assessments, metabolic panels, and histological evaluation. Emergency procedures should include capabilities for managing potential local reactions and systemic effects in research models receiving high PEG MGF doses.

PEG MGF Research Combinations for Comprehensive Muscle Studies

For advanced musculoskeletal investigations, PEG MGF may be studied alongside other Peptide Hubs products:

• IGF-1 LR3: For comparative studies on different IGF-1 isoform effects, combining systemic LR3 with localized PEG MGF actions.
• TB 500: In muscle repair research combining satellite cell activation (PEG MGF) with actin polymerization and cell migration (TB-500).
• BPC 157: For comprehensive tissue repair studies combining muscle growth mechanisms with angiogenesis and healing acceleration.
• CJC-1295/Ipamorelin: In studies exploring interactions between localized muscle growth factors and systemic growth hormone secretagogue effects.

These musculoskeletal research combinations should only be conducted by qualified investigators with appropriate expertise, following rigorous experimental designs, ethical guidelines, and institutional approvals specific to muscle biology research.

Specialized Packaging for Pegylated Peptides

Each PEG MGF research unit features packaging optimized for pegylated compound stability:

• One sterile amber glass vial with fluoropolymer-coated stopper containing 5 mg lyophilized PEG MGF
• Oxygen-absorbing packet and desiccant for enhanced stability during shipping and storage
• Tamper-evident holographic security seal ensuring product integrity and authentication
• Dual lot numbers, manufacture date, and specialized expiration documentation
• Comprehensive certificate of analysis including size-exclusion HPLC data confirming pegylation integrity
• Product insert with specific handling instructions for pegylated peptides
• Material Safety Data Sheet (MSDS) with pegylated compound handling guidelines
• Reconstitution guide addressing solubility considerations for PEG-conjugated peptides

Enhanced Storage for Pegylated Compound Stability

PEG MGF requires specific storage conditions to maintain conjugate integrity:

• Primary Storage: Store at -20°C (-4°F) in original packaging. For long-term storage, -80°C (-112°F) is recommended to preserve pegylation integrity.
• Temperature Consistency: Avoid temperature fluctuations which may affect PEG-peptide conjugate stability.
• Reconstituted Solution: Prepare immediately before experiments. Do not store reconstituted solution. If absolutely necessary, store at 2-8°C (36-46°F) for no more than 24 hours.
• Freeze-Thaw Cycles: Avoid freeze-thaw cycles which may damage PEG conjugation. Aliquot if multiple uses are anticipated.
• Stability Duration: Properly stored lyophilized powder maintains stability for 18 months. Monitor for activity in pilot experiments if stored near expiration.
• Pegylation Integrity: For critical studies, verify pegylation integrity via size-exclusion methods if stored extensively.
• Transport Conditions: Ship and transport with cold packs or dry ice to maintain temperature control and preserve conjugate structure.

PEG MGF Research Significance in Modern Muscle Biology

The availability of high-purity PEG MGF represents a significant advancement for contemporary muscle research. Pegylation technology addresses the fundamental limitation of native MGF—its extremely short half-life—while preserving its unique muscle-specific activities. The January 12, 2026 laboratory verification showing 5.75 mg content (115% purity) in the 5 mg vial demonstrates exceptional manufacturing precision for this technically challenging pegylated peptide. This quality assurance is particularly critical for muscle research where precise dosing directly influences satellite cell activation and hypertrophy outcomes. PEG MGF enables researchers to investigate sustained mechano growth factor signaling without the impractical dosing schedules required with native MGF. By maintaining localized effects while extending activity duration, it bridges the gap between acute mechanical signaling and chronic adaptive responses. The product's availability through Peptide Hubs, with verified purity and accurate dosing, supports rigorous investigation into fundamental mechanisms of muscle plasticity, repair, and growth that have broad implications for sports science, rehabilitation medicine, and age-related muscle loss research.

Third-Party Laboratory Verification

January 12, 2026

View Result

5.75 mg / 5 mg

The independent laboratory analysis conducted on January 12, 2026, confirms the PEG MGF vial contains 5.75 mg of active pegylated peptide content against the labeled 5 mg, representing a 115% purity rating that exceeds standard quality specifications. This exceptional verification ensures muscle biology researchers receive accurately dosed materials for investigations into satellite cell activation, muscle hypertrophy, and tissue repair mechanisms requiring precise quantification of pegylated growth factor activity.